Braidio says new Attruby data adds to Attr-CM.

• New data from an open -name study from Bridgebio Pharma (Nasdak:BbioAttuby (Acquisidis) showed that the drug has led to a significant decrease in cardiovascular deaths in individuals with amydidine myocardineine (Attr-CM).
• In 42 months after the vehicles, Attupy Lead To reduce 44 %

https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669838876/image_669838876.jpg?io=getty-c-w750

Source link